Tag Archives: exclusive commercialisation agreement

Fresenius Kabi Expands Oncology and Immunology Offering Through FDA-Approved Rituximab Biosimilar

Posted on 3, August 2026 by EuropaWire PR Editor

(IN BRIEF) Fresenius Kabi, an operating company of Fresenius, has announced that the U.S. FDA has approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories for the U.S. market. Under an exclusive commercialisation agreement, Fresenius Kabi holds the U.S. commercialisation … Read the full press release →

Posted in Business, Germany, Government, Healthcare, Pharma & Biotech, Science

Tagged #FutureFresenius, affordable biologic therapies, analytical data, autoimmune diseases, B cells, B lymphocytes, B-cell malignancies, Bad Homburg v. d. Höhe, biologic medicines, biopharma, biopharmaceuticals, Biosimilar, biosimilars portfolio, CD20 antigen, chronic lymphocytic leukemia, clinical data, clinical nutrition, Dr. Eduard Fresenius, Dr. Reddy’s, Dr. Reddy’s Laboratories, Dr. Sang-Jin Pak, Else Kröner, Else Kröner Fresenius Foundation, exclusive commercialisation agreement, FDA, FDA approval, FDA Approves Dr. Reddy’s Rituximab Biosimilar for U.S. Commercialisation by Fresenius Kabi, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Kabi Announces FDA Approval of Rituximab Biosimilar for U.S. Market, Fresenius Kabi Strengthens U.S. Biosimilars Portfolio With Rituximab Approval, Fresenius Medical Care, Fresenius SE & Co KGaA, Genentech, Germany, GPA, granulomatosis with polyangiitis, hematologic malignancies, immunology, intravenous generic drugs, medical technology, microscopic polyangiitis, monoclonal antibody, MPA, Nicole Meier, non-clinical data, Non-Hodgkin lymphoma, oncology, patient access, pharmacokinetic studies, rheumatoid arthritis, Rituxan, rituximab, rituximab biosimilar, totality of the evidence, U.S. Food and Drug Administration, U.S. market